Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Plans Joint Surprise Onsite Inspections by PMDA and Prefectural Govts
November 16, 2023
- MHLW Panel Pins Hope on PMDA’s Overseas Offices to Foster Global Appeal of Japan Market
November 16, 2023
- LDP Pharma Study Group Calls for Expanding Sakigake Premium, Creating New Premium
November 15, 2023
- Industry Can’t Endure Further Price Cuts for Creating Savings: LDP Health Affairs Chief
November 14, 2023
- Generic Study Group Discusses Industry Shake-Up through Consortia
November 14, 2023
- Japan Health Minister Seeks Industry Input for Detailed Discussions on Innovation Ecosystem
November 14, 2023
- Pfizer’s PARP Inhibitor, RSV Vaccine, Lilly’s IL-13 Med UP for Panel Review on Nov. 27
November 14, 2023
- 1.4 Billion Yen Booked as Emergency Subsidy for Drug Production Ramp-Up: FY2023 Extra Budget
November 13, 2023
- Japan Looks to Bolster Drug Discovery, Earmarks 240 Million Yen in FY2023 Extra Budget
November 13, 2023
- Generic Study Group Not Bound by Year-End Goal to Compile Final Report, Explore Best Solutions: MHLW Official
November 13, 2023
- Shionogi’s Cefiderocol Selected for Pilot-Based Revenue Assurance System
November 13, 2023
- Revisit 25-Plus-Year Listing Requirement for Essential Drugs: Chuikyo Members
November 13, 2023
- MHLW Proposes New Premium with Easier-than-Sakigake Requirements to Fight Lag, Loss
November 13, 2023
- Japan Panel Supports Certain Out-of-Pocket Payment for LLP-Generic Price Gap
November 10, 2023
- MHLW Proposes NIP Inclusion of 15-Valent Pneumococcal Vaccine for Kids
November 10, 2023
- Industry Prods Careful Debate on Creating Separate Rules for Leqembi Re-Pricing
November 9, 2023
- MHLW Cautions against Hoarding Oseltamivir Dry Syrup amid Tight Stocks
November 9, 2023
- Chugai’s Fujihara, Alfresa’s Arakawa to Represent Industry at Chuikyo
November 9, 2023
- Accumulate Knowledge to Prevent Dementia, a “National Issue”: PM Advisor
November 8, 2023
- Health Minister Asks 24 Makers to Raise Production of Antitussives, Expectorants; Firms Want Regulatory, Pricing Steps
November 8, 2023
ページ
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…